{"id":71489,"date":"2026-05-20T10:10:00","date_gmt":"2026-05-20T10:10:00","guid":{"rendered":"https:\/\/medsbase.com\/slu-pp-332\/"},"modified":"2026-05-21T07:14:09","modified_gmt":"2026-05-21T07:14:09","slug":"slu-pp-332","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/slu-pp-332\/","title":{"rendered":"SLU-PP-332 (Pan-ERR agonista napodobuj\u00edc\u00ed cvi\u010den\u00ed)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Rychl\u00e1 odpov\u011b\u010f \u2014 Co je SLU-PP-332?<\/h3>\n<p style=\"margin: 0;\"><strong>SLU-PP-332<\/strong> (CAS 303760-60-3, MF C<sub>18<\/sub>H<sub>14<\/sub>N<sub>2<\/sub>O<sub>2<\/sub>, MW 290.3 g\/mol) je syntetick\u00e1 mal\u00e1 molekula <strong>pan-agonista estrogen-souvisej\u00edc\u00edch receptor\u016f<\/strong> (ERR\u03b1 \/ ERR\u03b2 \/ ERR\u03b3) vyvinut\u00e1 v laborato\u0159i Burris na Saint Louis University. ERRs jsou sirot\u010d\u00ed transkrip\u010dn\u00ed faktory jadern\u00fdch receptor\u016f, kter\u00e9 \u0159\u00edd\u00ed mitochondri\u00e1ln\u00ed biogenezi, oxidaci mastn\u00fdch kyselin, v\u00fdvoj oxida\u010dn\u00edch vl\u00e1ken a svalov\u00fd adapta\u010dn\u00ed program norm\u00e1ln\u011b aktivovan\u00fd cvi\u010den\u00edm \u2014 co\u017e \u010din\u00ed SLU-PP-332 p\u0159edn\u00edm <strong>\u201ccvi\u010debn\u00edm mimetikem\u201d<\/strong> v\u00fdzkumn\u00fdm n\u00e1strojem. Publikov\u00e1no v Billon et al. (2023, <em>ACS Chemical Biology<\/em>) \u2014 akutn\u00ed jednor\u00e1zov\u00e9 pod\u00e1n\u00ed vyvol\u00e1v\u00e1 genovou signaturu odpov\u011bdi na aerobn\u00ed cvi\u010den\u00ed ve kostern\u00edm svalu; chronick\u00e9 pod\u00e1v\u00e1n\u00ed zvy\u0161uje pod\u00edl oxida\u010dn\u00edch vl\u00e1ken typu IIa a zlep\u0161uje vytrvalostn\u00ed kapacitu u my\u0161\u00ed. <em>Mal\u00e1 molekula \u2014 nikoli peptid.<\/em> Pozn\u00e1mka: n\u011bkter\u00e9 \u0161ar\u017ee od dodavatel\u016f jsou ozna\u010deny SLU-PP-322 \/ SLU-PP-332 zam\u011bniteln\u011b \u2014 oba n\u00e1zvy odkazuj\u00ed na stejn\u00fd pan-agonista ERR z Burrisovy laborato\u0159e; pro identifikaci konkr\u00e9tn\u00ed \u0161ar\u017ee se \u0159i\u010fte certifik\u00e1tem anal\u00fdzy (COA). Pouze pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> Lyofilizovan\u00fd SLU-PP-332 s \u010distotou \u226599% ov\u011b\u0159enou HPLC \u00b7 Certifik\u00e1t anal\u00fdzy (COA) na vy\u017e\u00e1d\u00e1n\u00ed \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 expedice pro v\u00fdzkumn\u00e9 \u00fa\u010dely \u00b7 1400+ ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px;\">Specifikace<\/th>\n<th style=\"padding: 8px 12px;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>T\u0159\u00edda slou\u010denin<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Syntetick\u00fd malomolekul\u00e1rn\u00ed pan-agonista estrogen-souvisej\u00edc\u00edch receptor\u016f (ERR\u03b1 \/ ERR\u03b2 \/ ERR\u03b3); agonista sirot\u010d\u00edch nukle\u00e1rn\u00edch receptor\u016f; v\u00fdzkumn\u00fd n\u00e1stroj napodobuj\u00edc\u00ed \u00fa\u010dinky cvi\u010den\u00ed; <em>nen\u00ed peptid<\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Chemick\u00fd n\u00e1zev<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">SLU-PP-332 (synonyma: SLU-PP-322 u n\u011bkter\u00fdch dodavatelsk\u00fdch \u0161ar\u017e\u00ed; pan-agonista ERR; slou\u010denina 332 z Burrisovy laborato\u0159e)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>CAS \u010d\u00edslo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">303760-60-3 (kanonick\u00e9 \u010d\u00edslo dle MedKoo \/ MedChemExpress \/ v\u011bdeck\u00e9 literatury)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>item2<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>18<\/sub>H<sub>14<\/sub>N<sub>2<\/sub>O<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>item7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">290.32 g\/mol<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Mechanismus \u00fa\u010dinku<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pan-agonista <strong>ERR\u03b1, ERR\u03b2, ERR\u03b3<\/strong> jadern\u00e9 receptory s ~4n\u00e1sobnou selektivitou pro ERR\u03b1 oproti ERR\u03b3. EC<sub>50<\/sub> ERR\u03b1 ~98 nM (Billon et al. 2023). Aktivace receptor\u016f ERR spou\u0161t\u00ed transkripci gen\u016f c\u00edlen\u00fdch PGC-1\u03b1 \u2014 mitochondri\u00e1ln\u00ed biogeneze (TFAM, NRF1, NRF2), \u03b2-oxidace mastn\u00fdch kyselin (CPT1B, MCAD, LCAD), podjednotky komplex\u016f oxidativn\u00ed fosforylace a myosinov\u00e9 t\u011b\u017ek\u00e9 \u0159et\u011bzce oxidativn\u00edch svalov\u00fdch vl\u00e1ken. \u010cist\u00fd efekt napodobuje transkrip\u010dn\u00ed program adaptace na cvi\u010den\u00ed.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>item9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">n\/a (syntetick\u00e1 n\u00edzkomolekul\u00e1rn\u00ed slou\u010denina \u2014 nikoliv peptid)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>item11<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyofilizovan\u00fd b\u00edl\u00fd a\u017e sv\u011btle \u017elut\u00fd pr\u00e1\u0161ek; jednor\u00e1zov\u00e9 v\u00fdzkumn\u00e9 lahvi\u010dky<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>item13<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC ov\u011b\u0159eno, COA na vy\u017e\u00e1d\u00e1n\u00ed)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Rozpustnost<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">DMSO \u226550 mg\/mL; vodn\u00e1 rozpustnost st\u0159edn\u00ed (pod 1 mg\/mL). Pro in-vitro pr\u00e1ci p\u0159ipravte z\u00e1soby v DMSO a \u0159ed\u011bte do kultiva\u010dn\u00edho m\u00e9dia t\u011bsn\u011b p\u0159ed pou\u017eit\u00edm. Pro in-vivo aplikace se obvykle pou\u017e\u00edvaj\u00ed formulace s DMSO\/PEG\/fyziologick\u00fdm roztokem nebo podobn\u00fdmi kosolventn\u00edmi syst\u00e9my.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Skladov\u00e1n\u00ed<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyofilizovan\u00fd: 2\u20138 \u00b0C kr\u00e1tkodob\u011b, \u221220 \u00b0C dlouhodob\u011b (\u226536 m\u011bs\u00edc\u016f). Rekonstituovan\u00fd v DMSO: \u221220 \u00b0C, jednor\u00e1zov\u00e9 rozmrazen\u00ed. Chra\u0148te p\u0159ed sv\u011btlem. Vyhn\u011bte se opakovan\u00e9mu zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Pouze pro v\u00fdzkum<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pouze pro laboratorn\u00ed v\u00fdzkum. Nen\u00ed ur\u010deno pro diagnostick\u00e9 nebo terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed nebo zv\u00ed\u0159at. Nen\u00ed aktu\u00e1ln\u011b na Seznamu zak\u00e1zan\u00fdch l\u00e1tek WADA pod sv\u00fdm specifick\u00fdm n\u00e1zvem, ale v\u00fdzkumn\u00edci by m\u011bli b\u00fdt v\u011bdomi, \u017ee \u0161ir\u0161\u00ed t\u0159\u00edda S4 (Hormon\u00e1ln\u00ed a metabolick\u00e9 modul\u00e1tory) zahrnuje l\u00e1tky napodobuj\u00edc\u00ed cvi\u010den\u00ed a regula\u010dn\u00ed status SLU-PP-332 se m\u016f\u017ee vyv\u00edjet.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Mechanismus \u00fa\u010dinku \u2014 pan-ERR agonismus \u0159\u00edd\u00ed transkripci adaptace na cvi\u010den\u00ed<\/h2>\n<p>SLU-PP-332 je nej\u010dast\u011bji citovan\u00fd syntetick\u00fd n\u00edzkomolekul\u00e1rn\u00ed pan-agonista ERR v publikovan\u00e9 literatu\u0159e. ERRs (estrogenem p\u0159\u00edbuzn\u00e9 receptory \u03b1, \u03b2, \u03b3) jsou sirot\u010d\u00ed jadern\u00e9 receptory, kter\u00e9 sd\u00edlej\u00ed vazebnou dom\u00e9nu pro DNA s estrogenn\u00edmi receptory, ale nev\u00e1\u017eou estrogen \u2014 jsou konstitutivn\u011b aktivn\u00ed v nep\u0159\u00edtomnosti jak\u00e9hokoliv p\u0159irozen\u00e9ho endogenn\u00edho ligandu a m\u00edsto toho jsou regulov\u00e1ny vazbou kofaktor\u016f (nejd\u016fle\u017eit\u011bji PGC-1\u03b1). ERRs jsou hlavn\u00ed transkrip\u010dn\u00ed hnac\u00ed s\u00edly:<\/p>\n<ul>\n<li><strong>Mitochondri\u00e1ln\u00ed biogeneze<\/strong> \u2014 p\u0159\u00edm\u00e1 transkrip\u010dn\u00ed kontrola TFAM, NRF1, NRF2 a des\u00edtek gen\u016f pro import mitochondri\u00e1ln\u00edch protein\u016f<\/li>\n<li><strong>\u03b2-oxidace mastn\u00fdch kyselin<\/strong> \u2014 indukce CPT1B (karnitin palmitoyltransfer\u00e1za 1B), MCAD, LCAD a dal\u0161\u00edch enzym\u016f \u03b2-oxidace<\/li>\n<li><strong>Oxidativn\u00ed fosforylace<\/strong> \u2014 transkripce jadern\u011b k\u00f3dovan\u00fdch podjednotek elektronov\u00e9ho transportn\u00edho \u0159et\u011bzce<\/li>\n<li><strong>V\u00fdvoj oxidativn\u00edch vl\u00e1ken<\/strong> \u2014 Indukce myosinov\u00e9ho t\u011b\u017ek\u00e9ho \u0159et\u011bzce typu IIa (oxidativn\u00ed rychl\u00e1 vl\u00e1kna); p\u0159em\u011bna glykolytick\u00fdch vl\u00e1ken typu IIb na oxidativn\u00ed vl\u00e1kna typu IIa<\/li>\n<li><strong>Adaptace metabolismu gluk\u00f3zy<\/strong> \u2014 zlep\u0161en\u00e1 inzulinov\u00e1 senzitivita kostern\u00edho svalstva u my\u0161\u00edch model\u016f s dietou indukovanou obezitou (DIO)<\/li>\n<\/ul>\n<p>Jedn\u00e1 se o stejn\u00fd transkrip\u010dn\u00ed program, kter\u00fd je aktivov\u00e1n adaptac\u00ed na cvi\u010den\u00ed \u0159\u00edzenou PGC-1\u03b1 \u2014 co\u017e z agonismu pan-ERR \u010din\u00ed p\u0159\u00edmou farmakologickou cestu k fenotypu adaptace na cvi\u010den\u00ed. Billon et al. (2023) <em>ACS Chemical Biology<\/em> prok\u00e1zali, \u017ee akutn\u00ed jednor\u00e1zov\u00e1 d\u00e1vka SLU-PP-332 vyvol\u00e1v\u00e1 v kostern\u00edm svalu my\u0161\u00ed genovou expresn\u00ed signaturu, kter\u00e1 se v\u00fdrazn\u011b p\u0159ekr\u00fdv\u00e1 se signaturou vzniklou p\u0159i b\u011bhu na kole\u010dku \u2014 a chronick\u00e9 pod\u00e1v\u00e1n\u00ed (50 mg\/kg\/den intraperitone\u00e1ln\u011b po dobu 4 t\u00fddn\u016f) zvy\u0161uje pod\u00edl vl\u00e1ken typu IIa a vytrvalost na b\u011bhac\u00edm p\u00e1su u my\u0161\u00ed. N\u00e1sledn\u00e1 pr\u00e1ce (Billon et al. 2024, zm\u00edrn\u011bn\u00ed metabolick\u00e9ho syndromu) prok\u00e1zala \u00fa\u010dinky na zlep\u0161en\u00ed metabolismu u my\u0161\u00ed s DIO, v\u010detn\u011b zlep\u0161en\u00ed gluk\u00f3zov\u00e9 tolerance a sn\u00ed\u017een\u00ed jatern\u00ed steat\u00f3zy.<\/p>\n<h2>Publikovan\u00e9 v\u00fdzkumn\u00e9 aplikace<\/h2>\n<ul>\n<li><strong>Farmakologie pan-ERR receptor\u016f<\/strong> \u2014 kanonick\u00e1 referen\u010dn\u00ed n\u00edzkomolekul\u00e1rn\u00ed slou\u010denina jako pan-agonista ERR<\/li>\n<li><strong>V\u00fdzkum transkrip\u010dn\u00ed mimikry cvi\u010den\u00ed<\/strong> \u2014 publikov\u00e1n jako p\u0159edn\u00ed slou\u010denina \u201ccvi\u010den\u00ed v tablet\u011b\u201d spolu s <a href=\"https:\/\/medsbase.com\/cs\/aicar-acadesine\/\">AICAR<\/a>; mechanisticky odli\u0161n\u00fd (p\u0159\u00edm\u00fd \u00fa\u010dinek na ERR vs. AMPK-AMP mimikry)<\/li>\n<li><strong>V\u00fdzkum mitochondri\u00e1ln\u00ed biogeneze<\/strong> \u2014 p\u0159\u00edm\u00fd transkrip\u010dn\u00ed aktiv\u00e1tor osy TFAM \/ NRF1 \/ NRF2<\/li>\n<li><strong>V\u00fdzkum adaptace kostern\u00edho svalstva<\/strong> \u2014 indukce oxidativn\u00edch vl\u00e1ken typu IIa, fenotyp zv\u00fd\u0161en\u00e9 vytrvalostn\u00ed v\u00fdkonnosti<\/li>\n<li><strong>V\u00fdzkum metabolick\u00e9ho syndromu<\/strong> \u2014 my\u0161\u00ed modely DIO, jatern\u00ed steat\u00f3za, inzulinov\u00e1 senzitivita<\/li>\n<li><strong>Farmakologie dr\u00e1hy PGC-1\u03b1<\/strong> \u2014 aktivuje transkrip\u010dn\u00ed kask\u00e1du \u0159\u00edzenou PGC-1\u03b1 z downstream<\/li>\n<\/ul>\n<p>Pro \u0161ir\u0161\u00ed kontext viz <a href=\"https:\/\/medsbase.com\/cs\/aicar-acadesine\/\">AICAR<\/a> (kanonick\u00e9 AMPK-zprost\u0159edkovan\u00e9 mimikum cvi\u010den\u00ed \u2014 odli\u0161n\u00fd mechanismus), <a href=\"https:\/\/medsbase.com\/cs\/aod-9604\/\">AOD-9604<\/a> (lipolytick\u00fd v\u00fdzkumn\u00fd peptid pouze na odbour\u00e1v\u00e1n\u00ed tuk\u016f), <a href=\"https:\/\/medsbase.com\/cs\/mots-c\/\">MOTS-c<\/a> (mitochondri\u00e1ln\u011b odvozen\u00fd peptid), <a href=\"https:\/\/medsbase.com\/cs\/5-amino-1mq\/\">5-Amino-1MQ<\/a> (inhibitor NNMT na ose NAD), <a href=\"https:\/\/medsbase.com\/cs\/nad\/\">NAD\u207a<\/a> (koenzym elektronov\u00e9ho transportu).<\/p>\n<h2>Dostupn\u00e9 s\u00edly<\/h2>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px;\">S\u00edla vialky<\/th>\n<th style=\"padding: 10px;\">Velikosti balen\u00ed<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong> \u2014 v\u00fdzkumn\u00fd standard; podporuje kohorty my\u0161\u00ed s DIO p\u0159i d\u00e1vce 50 mg\/kg\/den po dobu 4\u20138 t\u00fddn\u016f a in-vitro farmakologii v koncentrac\u00edch nM-\u00b5M<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Srovn\u00e1n\u00ed \u2014 SLU-PP-332 vs AICAR<\/h2>\n<p>SLU-PP-332 a <a href=\"https:\/\/medsbase.com\/cs\/aicar-acadesine\/\">AICAR<\/a> jsou dva nej\u010dast\u011bji citovan\u00e9 \u201cexercise mimetic\u201d v\u00fdzkumn\u00e9 slou\u010deniny v tomto katalogu, ale zapojuj\u00ed program adaptace na cvi\u010den\u00ed prost\u0159ednictv\u00edm mechanisticky odli\u0161n\u00fdch nad\u0159azen\u00fdch cest. SLU-PP-332 p\u0159\u00edmo aktivuje rodinu ERR (transkrip\u010dn\u00ed faktor pro program mitochondri\u00e1ln\u00ed biogeneze). AICAR aktivuje AMPK (nad\u0159azenou energetickou senzorovou kin\u00e1zu, kter\u00e1 mimo mnoho dal\u0161\u00edch \u00fa\u010dink\u016f stimuluje expresi PGC-1\u03b1 a koaktivaci PGC-1\u03b1-ERR). Ob\u011b slou\u010deniny tedy konverguj\u00ed ke stejn\u00e9 podpisov\u00e9 genov\u00e9 expresi, ale zapojuj\u00ed ji z r\u016fzn\u00fdch bod\u016f regula\u010dn\u00ed kask\u00e1dy.<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px;\">Krit\u00e9rium<\/th>\n<th style=\"padding: 10px;\">SLU-PP-332<\/th>\n<th style=\"padding: 10px;\">AICAR<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>MW<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">290.32 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">258.23 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Mechanismus \u00fa\u010dinku<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">P\u0159\u00edm\u00fd agonista nukle\u00e1rn\u00edho receptoru ERR\u03b1\/\u03b2\/\u03b3<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aktiv\u00e1tor AMPK (p\u0159es intracelul\u00e1rn\u00ed ZMP)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Bod z\u00e1sahu<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Downstream transkrip\u010dn\u00ed faktor<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nad\u0159azen\u00e1 energetick\u00e1 senzorov\u00e1 kin\u00e1za<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Nejl\u00e9pe prostudovan\u00e9 zam\u011b\u0159en\u00ed<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Indukce oxidativn\u00edch vl\u00e1ken typu IIa, fenotyp vytrvalosti<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Citlivost na inzul\u00edn, jatern\u00ed glukoneogeneze, \u0161ir\u0161\u00ed farmakologie AMPK<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typick\u00e1 d\u00e1vka<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">50 mg\/kg\/den IP (my\u0161, Billon\u016fv protokol)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">250\u2013500 mg\/kg\/den IP (my\u0161)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Status WADA<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">V sou\u010dasnosti nepojmenov\u00e1no<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Zak\u00e1z\u00e1no v\u017edy (S4.5)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Pot\u0159ebujete BAC vodu?<\/strong> Rekonstituce jak\u00e9hokoli lyofilizovan\u00e9ho vialu vy\u017eaduje steriln\u00ed bakteriostatickou vodu. Sp\u00e1rujte tento produkt s na\u0161\u00edm <a href=\"\/cs\/bac-water\/\"><strong>BAC Water (Bakteriostatick\u00e1 voda)<\/strong><\/a> \u2014 30 mL multid\u00e1vkov\u00fdm vialem, 0,9% benzylalkoholem konzervovan\u00fdm, USP-grade.<\/div>\n<h2>Skladov\u00e1n\u00ed a rekonstituce<\/h2>\n<p>Lyofilizovan\u00e9 lahvi\u010dky: skladujte p\u0159i 2\u20138 \u00b0C kr\u00e1tkodob\u011b, p\u0159i \u221220 \u00b0C dlouhodob\u011b. Rekonstituujte v DMSO p\u0159i pracovn\u00ed koncentraci \u226510 mg\/ml (vodn\u00e1 rozpustnost je omezen\u00e1; DMSO je preferovan\u00e9 rozpou\u0161t\u011bdlo). Pro in-vivo pr\u00e1ci formulujte s pomocn\u00fdmi rozpou\u0161t\u011bdly (DMSO\/PEG-400\/salin nebo podobn\u011b) t\u011bsn\u011b p\u0159ed pod\u00e1n\u00edm. Skladujte z\u00e1soby DMSO p\u0159i \u221220 \u00b0C, jednor\u00e1zov\u00e9 rozmrazen\u00ed. Chra\u0148te p\u0159ed sv\u011btlem. Vyhn\u011bte se opakovan\u00e9mu zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed.<\/p>\n<h2>\u010casto kladen\u00e9 ot\u00e1zky<\/h2>\n<h3>Je \u201cSLU-PP-322\u201d stejn\u00e9 jako SLU-PP-332?<\/h3>\n<p>N\u011bkter\u00e9 dodavatelsk\u00e9 \u0161ar\u017ee pou\u017e\u00edvaj\u00ed \u201cSLU-PP-322\u201d a \u201cSLU-PP-332\u201d zam\u011bniteln\u011b pro stejn\u00fd pan-agonista ERR od laborato\u0159e Burris. Kanonick\u00e9 v\u011bdeck\u00e9 ozna\u010den\u00ed je SLU-PP-332 (Billon et al. 2023, ACS Chemical Biology), s CAS 303760-60-3. Pro p\u0159esnou identifikaci se \u0159i\u010fte certifik\u00e1tem anal\u00fdzy (COA) \u0161ar\u017ee.<\/p>\n<h3>Jak\u00e9 publikovan\u00e9 d\u00e1vkov\u00e9 rozsahy byly pou\u017eity?<\/h3>\n<p>Protokoly pro in-vivo studie na my\u0161\u00edch pou\u017e\u00edvaj\u00ed 50 mg\/kg\/den intraperitone\u00e1ln\u011b po dobu 4\u20138 t\u00fddn\u016f (kanonick\u00fd protokol Billon et al.). Farmakologie in-vitro myotub a prim\u00e1rn\u00edch svalov\u00fdch bun\u011bk pou\u017e\u00edv\u00e1 100 nM a\u017e 10 \u00b5M v r\u016fstov\u00e9m m\u00e9diu. EC<sub>50<\/sub> pro ERR\u03b1 je ~98 nM.<\/p>\n<h3>\u010c\u00edm se SLU-PP-332 li\u0161\u00ed od ostatn\u00edch exercise mimetics?<\/h3>\n<p>SLU-PP-332 p\u0159\u00edmo aktivuje ERRs \u2013 transkrip\u010dn\u00ed faktory v downstreamov\u00e9 dr\u00e1ze. AICAR aktivuje AMPK (upstreamovou kin\u00e1zu). PPAR\u03b4 agonist\u00e9 z roku 2010 (GW501516) aktivuj\u00ed odli\u0161n\u00fd, ale \u010d\u00e1ste\u010dn\u011b p\u0159ekr\u00fdvaj\u00edc\u00ed se transkrip\u010dn\u00ed program. Odli\u0161n\u00fd mechanismus, \u010d\u00e1ste\u010dn\u011b p\u0159ekr\u00fdvaj\u00edc\u00ed se v\u00fdstup.<\/p>\n<h3>Je SLU-PP-332 na seznamu zak\u00e1zan\u00fdch l\u00e1tek WADA?<\/h3>\n<p>Aktu\u00e1ln\u011b nen\u00ed uveden pod sv\u00fdm specifick\u00fdm n\u00e1zvem, ale \u0161ir\u0161\u00ed t\u0159\u00edda S4 (Hormon\u00e1ln\u00ed a metabolick\u00e9 modul\u00e1tory) zahrnuje l\u00e1tky napodobuj\u00edc\u00ed cvi\u010den\u00ed. Regula\u010dn\u00ed status slou\u010deniny se m\u016f\u017ee vyv\u00edjet s p\u0159ib\u00fdvaj\u00edc\u00edmi v\u00fdzkumn\u00fdmi daty. V\u00fdzkumn\u00edci pracuj\u00edc\u00ed s lidsk\u00fdmi subjekty by m\u011bli konzultovat aktu\u00e1ln\u00ed seznam WADA.<\/p>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 20px 0 8px; border-radius: 4px; font-size: 14px;\"><strong>Pro\u010d objedn\u00e1vat v\u00fdzkumn\u00e9 slou\u010deniny od MedsBase:<\/strong> Lyofilizovan\u00e9 peptidy a slou\u010deniny HPLC \u226599% \u00b7 COA dostupn\u00e9 na vy\u017e\u00e1d\u00e1n\u00ed \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 p\u0159eprava \u00b7 <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance<\/a> na ka\u017edou objedn\u00e1vku \u00b7 1,400+ ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Dal\u0161\u00ed v\u00fdzkumn\u00e9 slou\u010deniny napodobuj\u00edc\u00ed cvi\u010den\u00ed \/ metabolick\u00fd v\u00fdzkum<\/h2>\n<ul>\n<li><a href=\"\/cs\/aicar-acadesine\/\"><strong>AICAR<\/strong><\/a> \u2014 Kanonick\u00fd AMPK-zprost\u0159edkovan\u00fd exercise mimetic \u2013 komplement\u00e1rn\u00ed mechanismus<\/li>\n<li><a href=\"\/cs\/aod-9604\/\"><strong>AOD-9604<\/strong><\/a> \u2014 Lipolytick\u00fd fragment C-konce hGH<\/li>\n<li><a href=\"\/cs\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondri\u00e1ln\u011b odvozen\u00fd metabolick\u00fd peptidov\u00fd aktiv\u00e1tor AMPK<\/li>\n<li><a href=\"\/cs\/5-amino-1mq\/\"><strong>5-Amino-1MQ<\/strong><\/a> \u2014 Inhibitor NNMT \u2013 \u0161et\u0159\u00edc\u00ed prekurzor NAD-osy<\/li>\n<li><a href=\"\/cs\/nad\/\"><strong>NAD\u207a<\/strong><\/a> \u2014 P\u0159\u00edm\u00e1 suplementace dinukleotidov\u00e9ho poolu<\/li>\n<li><a href=\"\/cs\/bac-water\/\"><strong>BAC Water (Bakteriostatick\u00e1 voda)<\/strong><\/a> \u2014 Nezbytn\u00e9 pro rekonstituci jak\u00e9hokoli lyofilizovan\u00e9ho vialu \u2014 steriln\u00ed \u0159edidlo s 0,9% konzervantem benzylalkoholu<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Syntetick\u00e1 mal\u00e1 molekula pan-agonista nukle\u00e1rn\u00edch receptor\u016f ERR\u03b1\/\u03b2\/\u03b3<br \/>\n\u2705 P\u0159\u00edm\u00fd transkrip\u010dn\u00ed aktiv\u00e1tor mitochondri\u00e1ln\u00ed biogeneze + indukce oxidativn\u00edch vl\u00e1ken<br \/>\n\u2705 Vedouc\u00ed v\u00fdzkumn\u00e1 slou\u010denina napodobuj\u00edc\u00ed cvi\u010den\u00ed (Billon et al. 2023, ACS Chem Biol)<br \/>\n\u2705 EC\u2085\u2080 ERR\u03b1 ~98 nM; ~4n\u00e1sobn\u00e1 selektivita pro ERR\u03b1 oproti ERR\u03b3<br \/>\n\u2705 N\u011bkte\u0159\u00ed dodavatel\u00e9 ozna\u010duj\u00ed jako SLU-PP-322; kanonick\u00fd n\u00e1zev SLU-PP-332; CAS 303760-60-3, MW 290.32<\/p>\n<p><strong>SLU-PP-332<\/strong> obsahuje syntetickou pan-ERR malou molekulu pro v\u00fdzkum. Nen\u00ed to peptid.<\/p>","protected":false},"featured_media":71525,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6536,6489,6535,6534,6482,6533,6532],"class_list":{"0":"post-71489","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-peptides","7":"product_tag-burris-lab-compound","8":"product_tag-exercise-mimetic","9":"product_tag-mitochondrial-biogenesis","10":"product_tag-pan-err-agonist","11":"product_tag-research-compound","12":"product_tag-slu-pp-322","13":"product_tag-slu-pp-332","15":"first","16":"instock","17":"shipping-taxable","18":"purchasable","19":"product-type-variable","20":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/71489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=71489"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/71525"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=71489"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=71489"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=71489"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=71489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}